PART I Overview We are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new class of RNA-targeting therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases. Our lead product candidate, CMP-002, has the potential to be the first disease-modifying therapy for the treatment of synaptic Ras GTPase activating protein 1 (SYNGAP1)-related disorder, or SYNGAP1, a severe developmental...
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001736730-26-000016 | EDGAR | 101K words |
| 2025-03-27 | 2024-12-31 | 0001736730-25-000022 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001736730-25-000094 | EDGAR | 23K words |
| 2025-08-14 | 2025-06-30 | 0001736730-25-000070 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001736730-25-000039 | EDGAR | — |
| 2024-11-21 | 2024-09-30 | 0001410578-24-002045 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-24 | 0001736730-26-000021 | EDGAR | 1K words |
| 2026-03-05 | 0001736730-26-000015 | EDGAR | — |
| 2026-01-09 | 0001736730-26-000004 | EDGAR | — |
| 2025-12-23 | 0001736730-25-000116 | EDGAR | — |
| 2025-12-18 | 0001628280-25-058009 | EDGAR | — |
| 2025-12-18 | 0001736730-25-000111 | EDGAR | — |
| 2025-11-06 | 0001736730-25-000092 | EDGAR | — |
| 2025-10-01 | 0001736730-25-000074 | EDGAR | — |
| 2025-09-10 | 0001736730-25-000072 | EDGAR | — |
| 2025-08-14 | 0001736730-25-000068 | EDGAR | — |
32 total filings indexed. 16 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001736730 |
| Ticker | CAMP |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.camp4tx.com |
| Listed | 2024-10-11 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report